ReviewNature reviews. Drug discovery2005
The evolving field of biodefence: therapeutic developments and diagnostics.
Review in Nature reviews. Drug discovery, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy.International journal of nanomedicine · 2025Article
- Article
- Protein biomarker elucidation for the verification of biological agents in the taxonomic group of Gammaproteobacteria using tandem mass spectrometry.World journal of microbiology & biotechnology · 2021Article
- Article
- Review
- Elucidation of protein biomarkers for verification of selected biological warfare agents using tandem mass spectrometry.Scientific reports · 2020Article
- Sepsis: mechanisms of bacterial injury to the patient.Scandinavian journal of trauma, resuscitation and emergency medicine · 2019Review
- Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.Pathogens and disease · 2018Article
- A review on the antagonist Ebola: A prophylactic approach.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2017Review
- Cellular Protection of SNAP-25 against Botulinum Neurotoxin/A: Inhibition of Thioredoxin Reductase through a Suicide Substrate Mechanism.Journal of the American Chemical Society · 2016Article
- Article
- Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized Screening.PloS one · 2016Article
- A monoclonal antibody to an abrin chimera recognizing a unique epitope on abrin A chain confers protection from abrin-induced lethality.Human vaccines & immunotherapeutics · 2016Article
- Epitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of botulinum neurotoxin.Angewandte Chemie (International ed. in English) · 2015Article
- Biochemical and structural analysis of an Eis family aminoglycoside acetyltransferase from bacillus anthracis.Biochemistry · 2015Article
- Probing BoNT/A protease exosites: implications for inhibitor design and light chain longevity.Biochemistry · 2014Article
- Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening.Journal of computer-aided molecular design · 2014Article
- Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.Journal of medicinal chemistry · 2014Article
- Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.Expert review of molecular diagnostics · 2014Review
- Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.Bioorganic & medicinal chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The threat of bioterrorism and the potential use of biological weapons against both military and civilian populations has become a major concern for governments around the world. For example, in 2001 anthrax-tainted letters resulted in several deaths, caused widespread public panic and exerted a heavy economic toll. If such a small-scale act of bioterrorism could have such a huge impact, then the effects of a large-scale attack would be catastrophic. This review covers recent progress in developing therapeutic countermeasures against, and diagnostics for, such agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.